Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$81.61
-2.1%
$84.17
$56.72
▼
$92.59
$30.35B1.455.03 million shs4.38 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,431.12
-0.9%
$1,247.93
$850.51
▼
$1,475.25
$1.34T0.43.00 million shs3.08 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$41.60
-0.1%
$39.99
$35.12
▼
$64.16
$181.50B0.711.35 million shs16.45 million shs
PepsiCo, Inc. stock logo
PEP
PepsiCo
$146.43
+0.7%
$133.81
$123.47
▼
$171.48
$193.86B0.319.60 million shs10.59 million shs
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$101.50
-1.7%
$95.83
$79.12
▼
$112.54
$19.79B0.52.38 million shs3.14 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%+4.94%-3.15%-6.12%+43.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+5.24%+14.79%+21.92%+40.93%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+3.18%+7.42%-7.21%-13.62%
PepsiCo, Inc. stock logo
PEP
PepsiCo
0.00%+2.90%+10.61%+5.21%-0.28%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.00%-2.14%+8.73%+5.15%+14.83%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$81.61
-2.1%
$84.17
$56.72
▼
$92.59
$30.35B1.455.03 million shs4.38 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,431.12
-0.9%
$1,247.93
$850.51
▼
$1,475.25
$1.34T0.43.00 million shs3.08 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$41.60
-0.1%
$39.99
$35.12
▼
$64.16
$181.50B0.711.35 million shs16.45 million shs
PepsiCo, Inc. stock logo
PEP
PepsiCo
$146.43
+0.7%
$133.81
$123.47
▼
$171.48
$193.86B0.319.60 million shs10.59 million shs
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$101.50
-1.7%
$95.83
$79.12
▼
$112.54
$19.79B0.52.38 million shs3.14 million shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
0.00%+4.94%-3.15%-6.12%+43.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+5.24%+14.79%+21.92%+40.93%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+3.18%+7.42%-7.21%-13.62%
PepsiCo, Inc. stock logo
PEP
PepsiCo
0.00%+2.90%+10.61%+5.21%-0.28%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.00%-2.14%+8.73%+5.15%+14.83%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
3.00
Buy$95.5017.02% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,422.00-0.64% Downside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.00
Hold$59.4442.89% Upside
PepsiCo, Inc. stock logo
PEP
PepsiCo
2.25
Hold$143.28-2.15% Downside
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
2.25
Hold$113.7912.11% Upside

Current Analyst Ratings Breakdown

Latest DXCM, LLY, NVO, PEP, and ZBH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,400.00 ➝ $1,550.00
11/16/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Lower Price TargetMarket Perform$102.00 ➝ $101.00
11/16/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Boost Price TargetBuy$125.00 ➝ $140.00
11/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B) ➝ Buy (B+)
11/13/2026
PepsiCo, Inc. stock logo
PEP
PepsiCo
Reiterated RatingMarket Perform
11/12/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy ➝ Hold
11/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,610.00 ➝ $1,700.00
11/9/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Boost Price TargetEqual Weight$100.00 ➝ $115.00
11/5/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Set Price Target$114.00
11/5/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Boost Price TargetBuy$120.00 ➝ $130.00
11/5/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
Boost Price TargetNeutral$117.00 ➝ $120.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$4.66B6.53$2.78 per share29.40$6.80 per share12.00
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B20.66$25.20 per share56.78$42.81 per share33.43
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$46.80B3.97$4.80 per share8.67$7.51 per share5.54
PepsiCo, Inc. stock logo
PEP
PepsiCo
$93.93B2.12$11.57 per share12.66$16.50 per share8.87
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$8.23B2.33$13.34 per share7.61$67.24 per share1.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$836.30M$2.5530.4826.501.3419.42%37.77%15.98%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8144.6728.221.7131.90%86.76%22.03%2/3/2027 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$3.9710.4512.061.4033.99%53.52%19.49%2/3/2027 (Estimated)
PepsiCo, Inc. stock logo
PEP
PepsiCo
$8.24B$7.9616.9216.954.2311.09%53.08%10.42%2/2/2027 (Estimated)
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$705.20M$3.9512.3311.402.458.95%13.02%7.17%N/A

Latest DXCM, LLY, NVO, PEP, and ZBH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$1.88$1.90+$0.02$1.00$2.04 billion$2.06 billion
10/29/2026Q3 2026
DexCom, Inc. stock logo
DXCM
DexCom
$0.6750$0.73+$0.0550$0.72$1.33 billion$1.34 billion
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
10/7/2026Q3 2026
PepsiCo, Inc. stock logo
PEP
PepsiCo
$2.29$2.34+$0.05$2.23$24.95 billion$25.27 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.48%+15.18%22.46%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.811.95%+21.74%20.40%N/A
PepsiCo, Inc. stock logo
PEP
PepsiCo
$5.924.04%+6.93%74.37%54 Years
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
$0.960.95%N/A24.30%N/A

Latest DXCM, LLY, NVO, PEP, and ZBH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.48%11/13/202611/13/202612/10/2026
8/28/2026
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
quarterly$0.241.08%9/30/20269/30/202610/30/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
0.49
1.74
1.40
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.54
0.84
0.64
PepsiCo, Inc. stock logo
PEP
PepsiCo
1.90
0.94
0.76
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
0.49
1.46
0.79

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
PepsiCo, Inc. stock logo
PEP
PepsiCo
73.07%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
88.89%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.28%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
PepsiCo, Inc. stock logo
PEP
PepsiCo
0.12%
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
1.28%
CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
11,000372.95 million371.91 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.74 million939.43 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
PepsiCo, Inc. stock logo
PEP
PepsiCo
306,0001.36 billion1.36 billionOptionable
Zimmer Biomet Holdings, Inc. stock logo
ZBH
Zimmer Biomet
17,000189.25 million186.83 millionOptionable

Recent News About These Companies

Zimmer Biomet (ZBH) PT Raised to $140 at Stifel
Zimmer Biomet (NYSE:ZBH) Stock Rating Raised to Buy at Wall Street Zen
Wall Street Zen Upgrades Zimmer Biomet (NYSE:ZBH) to "Buy"
What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call
Zimmer Biomet (NYSE:ZBH) Price Target Raised to $130.00
Zimmer Biomet Holdings (ZBH) Gets a Hold from Citi

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
DexCom stock logo

DexCom NASDAQ:DXCM

$81.61 -1.72 (-2.06%)
Closing price 04:00 PM Eastern
Extended Trading
$80.64 -0.97 (-1.19%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,431.12 -12.38 (-0.86%)
Closing price 03:59 PM Eastern
Extended Trading
$1,435.07 +3.96 (+0.28%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$41.60 -0.03 (-0.08%)
Closing price 03:59 PM Eastern
Extended Trading
$41.53 -0.07 (-0.16%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

PepsiCo stock logo

PepsiCo NASDAQ:PEP

$146.43 +0.99 (+0.68%)
Closing price 04:00 PM Eastern
Extended Trading
$146.72 +0.28 (+0.19%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PepsiCo, Inc. engages in the manufacture, marketing, distribution, and sale of various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products, as well as distributes alcoholic beverages under Hard MTN Dew brand. The company offers its products primarily under the Lay's, Doritos, Fritos, Tostitos, BaiCaoWei, Cheetos, Cap'n Crunch, Life, Pearl Milling Company, Gatorade, Pepsi-Cola, Mountain Dew, Quaker, Rice-A-Roni, Aquafina, Bubly, Emperador, Diet Mountain Dew, Diet Pepsi, Gatorade Zero, Crush, Propel, Dr Pepper, Schweppes, Marias Gamesa, Ruffles, Sabritas, Saladitas, Tostitos, 7UP, Diet 7UP, H2oh!, Manzanita Sol, Mirinda, Pepsi Black, Pepsi Max, San Carlos, Toddy, Walkers, Chipsy, Kurkure, Sasko, Spekko, White Star, Smith's, Sting, SodaStream, Lubimyj Sad, Agusha, Chudo, Domik v Derevne, Lipton, and other brands. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is based in Purchase, New York.

Zimmer Biomet stock logo

Zimmer Biomet NYSE:ZBH

$101.50 -1.71 (-1.66%)
Closing price 03:59 PM Eastern
Extended Trading
$101.42 -0.08 (-0.08%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers robotic, surgical, and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.